SEC Comment Letter for Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343) (LCTX) — May 6, 2020
Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343)
Date: May 6, 2020 · CIK: 0000876343 · Accession: 0000000000-20-003972
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237975
Letter
United States securities and exchange commission logo May 6, 2020 Chase Leavitt, Esq. General Counsel Lineage Cell Therapeutics, Inc. 2173 Salk Avenue Carlsbad, CA 92008 Re:Lineage Cell Therapeutics, Inc. Registration Statement on Form S-3 Filed May 1, 2020 File No. 333-237975 Dear Mr. Leavitt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven Przesmicki, Esq.
Show Raw Text
United States securities and exchange commission logo
May 6, 2020
Chase Leavitt, Esq.
General Counsel
Lineage Cell Therapeutics, Inc.
2173 Salk Avenue
Carlsbad, CA 92008
Re:Lineage Cell Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 1, 2020
File No. 333-237975
Dear Mr. Leavitt:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steven Przesmicki, Esq.